Cargando…

Evaluation of Mesenchymal Stem Cell Therapy for Sepsis: A Randomized Controlled Porcine Study

Background: Treatment with mesenchymal stem cells (MSCs) has elicited considerable interest as an adjunctive therapy in sepsis. However, the encouraging effects of experiments with MSC in rodents have not been adequately studied in large-animal models with better relevance to human sepsis. Objective...

Descripción completa

Detalles Bibliográficos
Autores principales: Horak, Jan, Nalos, Lukas, Martinkova, Vendula, Tegl, Vaclav, Vistejnova, Lucie, Kuncova, Jitka, Kohoutova, Michaela, Jarkovska, Dagmar, Dolejsova, Martina, Benes, Jan, Stengl, Milan, Matejovic, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7019005/
https://www.ncbi.nlm.nih.gov/pubmed/32117276
http://dx.doi.org/10.3389/fimmu.2020.00126
_version_ 1783497431684481024
author Horak, Jan
Nalos, Lukas
Martinkova, Vendula
Tegl, Vaclav
Vistejnova, Lucie
Kuncova, Jitka
Kohoutova, Michaela
Jarkovska, Dagmar
Dolejsova, Martina
Benes, Jan
Stengl, Milan
Matejovic, Martin
author_facet Horak, Jan
Nalos, Lukas
Martinkova, Vendula
Tegl, Vaclav
Vistejnova, Lucie
Kuncova, Jitka
Kohoutova, Michaela
Jarkovska, Dagmar
Dolejsova, Martina
Benes, Jan
Stengl, Milan
Matejovic, Martin
author_sort Horak, Jan
collection PubMed
description Background: Treatment with mesenchymal stem cells (MSCs) has elicited considerable interest as an adjunctive therapy in sepsis. However, the encouraging effects of experiments with MSC in rodents have not been adequately studied in large-animal models with better relevance to human sepsis. Objectives: Here, we aimed to assess safety and efficacy of bone marrow-derived MSCs in a clinically relevant porcine model of progressive peritonitis-induced sepsis. Methods: Thirty-two anesthetized, mechanically ventilated, and instrumented pigs were randomly assigned into four groups (n = 8 per group): (1) sham-operated group (CONTROL); (2) sham-operated group treated with MSCs (MSC-CONTROL); (3) sepsis group with standard supportive care (SEPSIS); and (4) sepsis group treated with MSCs (MSC-SEPSIS). Peritoneal sepsis was induced by inoculating cultivated autologous feces. MSCs (1 × 10(6)/kg) were administered intravenously at 6 h after sepsis induction. Results: Before, 12, 18, and 24 h after the induction of peritonitis, we measured systemic, regional, and microvascular hemodynamics, multiple-organ functions, mitochondrial energy metabolism, systemic immune-inflammatory response, and oxidative stress. Administration of MSCs in the MSC-CONTROL group did not elicit any measurable acute effects. Treatment of septic animals with MSCs failed to mitigate sepsis-induced hemodynamic alterations or the gradual rise in Sepsis-related organ failure assessment scores. MSCs did not confer any protection against sepsis-mediated cellular myocardial depression and mitochondrial dysfunction. MSCs also failed to modulate the deregulated immune-inflammatory response. Conclusion: Intravenous administration of bone marrow-derived MSCs to healthy animals was well-tolerated. However, in this large-animal, clinically relevant peritonitis-induced sepsis model, MSCs were not capable of reversing any of the sepsis-induced disturbances in multiple biological, organ, and cellular systems.
format Online
Article
Text
id pubmed-7019005
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-70190052020-02-28 Evaluation of Mesenchymal Stem Cell Therapy for Sepsis: A Randomized Controlled Porcine Study Horak, Jan Nalos, Lukas Martinkova, Vendula Tegl, Vaclav Vistejnova, Lucie Kuncova, Jitka Kohoutova, Michaela Jarkovska, Dagmar Dolejsova, Martina Benes, Jan Stengl, Milan Matejovic, Martin Front Immunol Immunology Background: Treatment with mesenchymal stem cells (MSCs) has elicited considerable interest as an adjunctive therapy in sepsis. However, the encouraging effects of experiments with MSC in rodents have not been adequately studied in large-animal models with better relevance to human sepsis. Objectives: Here, we aimed to assess safety and efficacy of bone marrow-derived MSCs in a clinically relevant porcine model of progressive peritonitis-induced sepsis. Methods: Thirty-two anesthetized, mechanically ventilated, and instrumented pigs were randomly assigned into four groups (n = 8 per group): (1) sham-operated group (CONTROL); (2) sham-operated group treated with MSCs (MSC-CONTROL); (3) sepsis group with standard supportive care (SEPSIS); and (4) sepsis group treated with MSCs (MSC-SEPSIS). Peritoneal sepsis was induced by inoculating cultivated autologous feces. MSCs (1 × 10(6)/kg) were administered intravenously at 6 h after sepsis induction. Results: Before, 12, 18, and 24 h after the induction of peritonitis, we measured systemic, regional, and microvascular hemodynamics, multiple-organ functions, mitochondrial energy metabolism, systemic immune-inflammatory response, and oxidative stress. Administration of MSCs in the MSC-CONTROL group did not elicit any measurable acute effects. Treatment of septic animals with MSCs failed to mitigate sepsis-induced hemodynamic alterations or the gradual rise in Sepsis-related organ failure assessment scores. MSCs did not confer any protection against sepsis-mediated cellular myocardial depression and mitochondrial dysfunction. MSCs also failed to modulate the deregulated immune-inflammatory response. Conclusion: Intravenous administration of bone marrow-derived MSCs to healthy animals was well-tolerated. However, in this large-animal, clinically relevant peritonitis-induced sepsis model, MSCs were not capable of reversing any of the sepsis-induced disturbances in multiple biological, organ, and cellular systems. Frontiers Media S.A. 2020-02-07 /pmc/articles/PMC7019005/ /pubmed/32117276 http://dx.doi.org/10.3389/fimmu.2020.00126 Text en Copyright © 2020 Horak, Nalos, Martinkova, Tegl, Vistejnova, Kuncova, Kohoutova, Jarkovska, Dolejsova, Benes, Stengl and Matejovic. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Horak, Jan
Nalos, Lukas
Martinkova, Vendula
Tegl, Vaclav
Vistejnova, Lucie
Kuncova, Jitka
Kohoutova, Michaela
Jarkovska, Dagmar
Dolejsova, Martina
Benes, Jan
Stengl, Milan
Matejovic, Martin
Evaluation of Mesenchymal Stem Cell Therapy for Sepsis: A Randomized Controlled Porcine Study
title Evaluation of Mesenchymal Stem Cell Therapy for Sepsis: A Randomized Controlled Porcine Study
title_full Evaluation of Mesenchymal Stem Cell Therapy for Sepsis: A Randomized Controlled Porcine Study
title_fullStr Evaluation of Mesenchymal Stem Cell Therapy for Sepsis: A Randomized Controlled Porcine Study
title_full_unstemmed Evaluation of Mesenchymal Stem Cell Therapy for Sepsis: A Randomized Controlled Porcine Study
title_short Evaluation of Mesenchymal Stem Cell Therapy for Sepsis: A Randomized Controlled Porcine Study
title_sort evaluation of mesenchymal stem cell therapy for sepsis: a randomized controlled porcine study
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7019005/
https://www.ncbi.nlm.nih.gov/pubmed/32117276
http://dx.doi.org/10.3389/fimmu.2020.00126
work_keys_str_mv AT horakjan evaluationofmesenchymalstemcelltherapyforsepsisarandomizedcontrolledporcinestudy
AT naloslukas evaluationofmesenchymalstemcelltherapyforsepsisarandomizedcontrolledporcinestudy
AT martinkovavendula evaluationofmesenchymalstemcelltherapyforsepsisarandomizedcontrolledporcinestudy
AT teglvaclav evaluationofmesenchymalstemcelltherapyforsepsisarandomizedcontrolledporcinestudy
AT vistejnovalucie evaluationofmesenchymalstemcelltherapyforsepsisarandomizedcontrolledporcinestudy
AT kuncovajitka evaluationofmesenchymalstemcelltherapyforsepsisarandomizedcontrolledporcinestudy
AT kohoutovamichaela evaluationofmesenchymalstemcelltherapyforsepsisarandomizedcontrolledporcinestudy
AT jarkovskadagmar evaluationofmesenchymalstemcelltherapyforsepsisarandomizedcontrolledporcinestudy
AT dolejsovamartina evaluationofmesenchymalstemcelltherapyforsepsisarandomizedcontrolledporcinestudy
AT benesjan evaluationofmesenchymalstemcelltherapyforsepsisarandomizedcontrolledporcinestudy
AT stenglmilan evaluationofmesenchymalstemcelltherapyforsepsisarandomizedcontrolledporcinestudy
AT matejovicmartin evaluationofmesenchymalstemcelltherapyforsepsisarandomizedcontrolledporcinestudy